Who are S-1 [Tegafur/Oteracil/gimeracil]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Erlotinib, Pemetrexed, Flutron, XELODA [capecitabine].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-1-tegafur-oteracil-gimeracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

S-1 [Tegafur/Oteracil/gimeracil] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S-1 [Tegafur/Oteracil/gimeracil] (S-1 [Tegafur/Oteracil/gimeracil]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agent. Area: Oncology.

phase 3 Antineoplastic agent Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

S-1 [Tegafur/Oteracil/gimeracil] (S-1 [Tegafur/Oteracil/gimeracil]) — AstraZeneca. S-1 works by inhibiting thymidylate synthase, which is necessary for DNA synthesis, thereby inducing apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
S-1 [Tegafur/Oteracil/gimeracil] TARGET	S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	phase 3	Antineoplastic agent	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Flutron	DOXIFLURIDINE		marketed	doxifluridine	Thymidylate synthase
XELODA [capecitabine]	XELODA [capecitabine]	Hoffmann-La Roche	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agent class)

Acrotech Biopharma Inc. · 1 drug in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Cephalon, Inc. · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Seattle Project Corporation · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S-1 [Tegafur/Oteracil/gimeracil] — Competitive Intelligence Brief. https://druglandscape.com/ci/s-1-tegafur-oteracil-gimeracil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab